Literature DB >> 10706891

Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer.

P Stiff1, B Chen, W Franklin, D Oldenberg, E Hsi, R Bayer, E Shpall, J Douville, R Mandalam, D Malhotra, T Muller, R D Armstrong, A Smith.   

Abstract

The collection of small aliquots of bone marrow (BM), followed by ex vivo expansion for autologous transplantation may be less morbid, and more cost-effective, than typical BM or blood stem cell harvesting. Passive elimination of contaminating tumor cells during expansion could reduce reinoculation risks. Nineteen breast cancer patients underwent autotransplants exclusively using ex vivo expanded small aliquot BM cells (900-1200 x 10(6)). BM was expanded in media containing recombinant flt3 ligand, erythropoietin, and PIXY321, using stromal-based perfusion bioreactors for 12 days, and infused after high-dose chemotherapy. Correlations between cell dose and engraftment times were determined, and immunocytochemical tumor cell assays were performed before and after expansion. The median volume of BM expanded was 36.7 mL (range 15.8-87.0). Engraftment of neutrophils greater than 500/microL and platelets greater than 20,000/microL were 16 (13-24) and 24 (19-45) days, respectively; 1 patient had delayed platelet engraftment, even after infusion of back-up BM. Hematopoiesis is maintained at 24 months, despite posttransplant radiotherapy in 18 of the 19 patients. Transplanted CD34(+)/Lin(-) (lineage negative) cell dose correlated with neutrophil and platelet engraftment, with patients receiving greater than 2.0 x 10(5) CD34(+)/Lin(-) cells per kilogram, engrafting by day 28. Tumor cells were observed in 1 of the 19 patients before expansion, and in none of the 19 patients after expansion. It is feasible to perform autotransplants solely with BM cells grown ex vivo in perfusion bioreactors from a small aliquot. Engraftment times are similar to those of a typical 1000 to 1500 mL BM autotransplant. If verified, this procedure could reduce the risk of tumor cell reinoculation with autotransplants and may be valuable in settings in which small stem cell doses are available, eg, cord blood transplants. (Blood. 2000;95:2169-2174)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706891

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Angiogenic and osteogenic potential of bone repair cells for craniofacial regeneration.

Authors:  Darnell Kaigler; Giorgio Pagni; Chan-Ho Park; Susan A Tarle; Ronnda L Bartel; William V Giannobile
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

Review 2.  Ex vivo expansion of human hematopoietic stem cells.

Authors:  T Nakahata
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 3.  Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application.

Authors:  R Aggarwal; J Lu; V J Pompili; H Das
Journal:  Curr Mol Med       Date:  2012-01       Impact factor: 2.222

4.  Potential for a pluripotent adult stem cell treatment for acute radiation sickness.

Authors:  Denis O Rodgerson; Bruce E Reidenberg; Alan G Harris; Andrew L Pecora
Journal:  World J Exp Med       Date:  2012-06-20

5.  Mouse mesenchymal stem cells can support human hematopoiesis both in vitro and in vivo: the crucial role of neural cell adhesion molecule.

Authors:  Xiaoli Wang; Hiroko Hisha; Tomomi Mizokami; Wenhao Cui; Yunze Cui; Aiping Shi; Changye Song; Satoshi Okazaki; Qing Li; Wei Feng; Junko Kato; Susumu Ikehara
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  Determination of the fate and contribution of ex vivo expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP.

Authors:  Dezhong Yin; Zhuo Wang; Qinghong Gao; Renuka Sundaresan; Chris Parrish; Qingfen Yang; Paul H Krebsbach; Alexander C Lichtler; David W Rowe; Janet Hock; Peng Liu
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

7.  In Vitro Expansion of Hematopoietic Stem Cells by Inhibition of Both GSK3 and p38 Signaling.

Authors:  Jing Li; Lei Zhang; Lizhi Yin; Na Ma; Tian Wang; Yuanyuan Wu; Ming Wang; Xingxing Yang; Hui Xu; Caiqin Hao; Wenyan Li; Wei Wei; Yan Xu; Feng Zhang; Peter Breslin; Jiwang Zhang; Jun Zhang
Journal:  Stem Cells Dev       Date:  2019-10-29       Impact factor: 4.390

8.  Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.

Authors:  Che K Lim; Li Sun; Qi Feng; Ping Law; Wei T Chua; Shy N Lim; William Y K Hwang
Journal:  J Hematol Oncol       Date:  2008-10-23       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.